The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  European Journal of Cancer

• Publication date

  1998-11-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/S0959-8049(98)00222-6PMID 10023306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?

  1997cited by this paper
• Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.

  1997cited by this paper
• Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.

  1997cited by this paper
• Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.

  1997cited by this paper
• Cancer statistics, 1997

  1997cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia

  1997cited by this paper
• Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.

  1997cited by this paper
• Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial

  1997cited by this paper
• Incorporation of Quality-of-Life Considerations into Decision Models for the Use of Colony-Stimulating Factors in Chemotherapy Patients at Risk for Febrile Neutropenia

  1997cited by this paper
• A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.

  1997cited by this paper
• Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease. A randomised economic study.

  1997cited by this paper
• Filgrastim (r-metHuG-CSF): the first 10 years.

  1996cited by this paper
• Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation.

  1996cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

  1996cited by this paper
• Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.

  1996cited by this paper
• Cancer statistics, 1996

  1996cited by this paper
• Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

  1996cited by this paper
• Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.

  1996cited by this paper
• Recommendations for Reporting Cost-effectiveness Analyses

  1996cited by this paper
• A cost analysis of hematopoietic colony-stimulating factors.

  1995cited by this paper
• Measuring the cost-effectiveness of cancer care.

  1995cited by this paper
• Health care costs: market forces and reform.

  1995cited by this paper
• A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

  1995cited by this paper
• Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.

  1995cited by this paper
• The costs of cancer care in the United States: implications for action.

  1995cited by this paper
• Diagnostic and management issues in gallbladder carcinoma.

  1995cited by this paper
• Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.

  1994cited by this paper
• Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.

  1994cited by this paper
• Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.

  1994cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

  1994cited by this paper
• The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.

  1994cited by this paper
• Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.

  1993cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

  1993cited by this paper
• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.

  1993cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• The national economic burden of cancer: an update.

  1990cited by this paper
• Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.

  1989cited by this paper
• Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

  1988cited by this paper
• A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.

  1986cited by this paper
• Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

  1966cited by this paper

• The impact of neutropenia severity in the setting of recent chemotherapy on mortality in sepsis

  2025cites this paper
• Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting

  2024cites this paper
• Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital

  2023cites this paper
• Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab

  2022cites this paper
• Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies

  2021cites this paper
• Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars

  2021cites this paper
• Management Costs of Febrile Neutropenia in Oncology Patients in Colombia

  2021cites this paper
• A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

  2019cites this paper
• Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.

  2019cites this paper
• Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years

  2019cites this paper
• Incidence and attributes of chemotherapy induced myelotoxicity, anemia and neutropenia in adults with cancer in Nepal: A cross-sectional observational study

  2018cites this paper
• Home Testing of Blood Counts in Patients with Cancer

  2018influential citation
• Cost‐effectiveness of granulocyte colony‐stimulating factor prophylaxis in chemotherapy‐induced febrile neutropenia among breast cancer and Non‐Hodgkin's lymphoma patients under Taiwan's national health insurance system

  2017cites this paper
• La Gaceta Mexicana de Oncología (GAMO) evoluciona en su publicación

  2017cites this paper
• Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events

  2017cites this paper
• Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region

  2017cites this paper
• Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.

  2017cites this paper
• Cost-Benefit Study of Febrile Neutropenia Prophylactic Treatment with Pegfilgrastim vs. Filgrastim in Pediatric Patients with Solid Tumors

  2017cites this paper
• Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy: A SEER-Medicare-based Study

  2017cites this paper
• Estudio de costo-beneficio del tratamiento profiláctico de la neutropenia febril con pegfilgrastim versus filgrastim en pacientes pediátricos con tumores sólidos

  2017cites this paper
• Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review

  2016cites this paper
• Title : The febrile neutropenia threshold for primary G-CSF prophylaxis in breast cancer

  2016cites this paper
• COST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA

  2016cites this paper
• Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences.

  2016cites this paper
• Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels – A Strategy for Brain Cancer Treatments

  2016cites this paper
• Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy

  2015cites this paper
• Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design.

  2015cites this paper
• Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.

  2015cites this paper
• Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

  2015cites this paper
• Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia.

  2014cites this paper
• Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

  2014cites this paper
• Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.

  2014cites this paper
• G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use

  2014cites this paper
• Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen, in Terms of Safety and Efficacy, in Healthy Volunteers and Patients Receiving Myelosuppressive Chemotherapy

  2014cites this paper
• The use of granulocyte colony-stimulating factors in a Canadian outpatient setting.

  2014cites this paper
• Nanoparticle based strategies for the treatment of Glioblastoma

  2014cites this paper
• Pharmacoeconomics of Granulocyte Colony-Stimulating Factor: A Critical Review

  2014cites this paper
• Costs Associated with Febrile Neutropenia

  2014cites this paper
• A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia

  2013cites this paper
• Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses

  2013cites this paper
• Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

  2013cites this paper
• Is primary prophylaxis with granulocyte colony stimulating factor (G-CSF) indicated in the treatment of lymphoma?

  2013cites this paper
• Myeloid growth factors.

  2013cites this paper
• Short-term costs associated with primary prophylactic G-CSF use during chemotherapy.

  2013cites this paper
• Clinical implications, safety, efficacy of Recombinant Human Granulocyte Colony-Stimulating Factors and Pegylated Equivalent

  2013cites this paper
• Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

  2012cites this paper
• Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer

  2012cites this paper
• Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier

  2012cites this paper
• Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice

  2012cites this paper
• Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors

  2012cites this paper
• Pharmacoeconomics of the Myeloid Growth Factors

  2012cites this paper
• Economic evaluations of granulocyte colony-stimulating factor

  2012cites this paper
• Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy

  2011cites this paper
• Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy.

  2011cites this paper
• Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.

  2011cites this paper
• Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

  2011cites this paper
• Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer

  2011cites this paper
• Characterized Polysaccharides from Black Soybean Induce Granulocyte Colony-Stimulated Factor Gene Expression in a Phosphoinositide 3-Kinase-dependent Manner

  2011cites this paper
• Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer

  2011cites this paper
• The Characterization and Potential use of G-CSF Dimers and their Pegylated Conjugates.

  2011cites this paper
• The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset

  2011cites this paper
• Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.

  2011cites this paper
• Ressourcenverbrauch und direkte Kosten in der Behandlung der Chemotherapie-assoziierten febrilen Neutropenie bei Patientinnen mit primärem Mammakarzinom

  2010cites this paper
• Colony stimulating factors for afebrile neutropenia in cancer patients

  2010cites this paper
• Oncologic Emergencies, Part II: Neutropenic Fever, Tumor Lysis Syndrome, And Hypercalcemia

  2010cites this paper
• A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

  2010cites this paper
• Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.

  2009cites this paper
• Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy

  2009cites this paper
• Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

  2009cites this paper
• Dose adjustment and supportive care before and during treatment.

  2009cites this paper
• Impact of effective prevention and management of febrile neutropenia

  2009cites this paper
• Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.

  2009cites this paper
• Análisis económico del uso profiláctico de factores estimulantes de colonias para prevenir eventos de neutropenia febril en pacientes que reciben quimioterapia mieloablativa

  2009cites this paper
• Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

  2008cites this paper
• Management of Chemotherapy-induced Neutropenia with Colony-stimulating Factors

  2008cites this paper
• Cost of neutropenic complications of chemotherapy.

  2008cites this paper
• Managing Hematologic Toxicities in the Oncology Patient

  2007cites this paper
• Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

  2007cites this paper
• Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.

  2007cites this paper
• Granulocyte colony-stimulating factors: finding the right indication

  2007cites this paper
• Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

  2007cites this paper
• Economic Burden of Haematological Adverse Effects in Cancer Patients

  2007cites this paper
• Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.

  2007cites this paper
• Estimating the costs of chemotherapy-associated adverse event clusters

  2007influential citation
• Agents under investigation for the treatment and prevention of neutropenia

  2007cites this paper
• Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies

  2007cites this paper
• Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

  2006cites this paper
• [G-CSF in oncology].

  2006cites this paper
• [Prognostic factors for febrile neutropenia].

  2006cites this paper
• Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

  2006cites this paper
• Haematopoietic Growth Factors: Therapeutic Uses

  2006cites this paper
• Chemotherapy dose intensity and quality cancer care.

  2006cites this paper
• Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors

  2006cites this paper
• Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

  2006cites this paper
• Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.

  2006cites this paper
• Hematopoietic support with moderately myelosuppressive chemotherapy regimens: a nursing perspective.

  2006cites this paper
• Moving beyond febrile neutropenia.

  2005cites this paper
• Protocols for Managing Chemotherapy‐induced Neutropenia in Clinical Oncology Practices

  2005cites this paper
• First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

  2005cites this paper
• Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.

  2005cites this paper